论文部分内容阅读
目的观察拉米夫定联合白细胞介素2抗HBV的疗效的安全性。方法将73例病例随机分为观察组(拉米夫定联合白细胞介素2、乙肝疫苗)和对照组(单用拉米夫定),其中观察组40例,对照组33例。结果治疗12个月后,观察组和对照组的ALT复常率分别为97.5%和81.8%(P<0.05),HBeAg、HBVDNA阴转率差异显著性P<0.05。结论拉米夫定联合白细胞介素2、乙肝疫苗治疗CHB安全有效优于单用拉米夫定。
Objective To observe the safety of lamivudine combined with interleukin-2 in anti-HBV therapy. Methods 73 cases were randomly divided into observation group (lamivudine combined with interleukin 2 and hepatitis B vaccine) and control group (lamivudine alone), in which 40 cases in the observation group and 33 cases in the control group. Results After 12 months of treatment, the ALT abnormalities in the observation group and the control group were 97.5% and 81.8%, respectively (P <0.05). The negative conversion rates of HBeAg and HBVDNA were significantly different between two groups (P <0.05). Conclusions Lamivudine combined with interleukin-2 and hepatitis B vaccine is safe and effective in treating CHB than lamivudine alone.